Cyclin-dependent kinase inhibitor 1A promoter (CDKN1A promoter) (p21 promoter)

The Cyclin-dependent kinase inhibitor 1A (CDKN1A) promoter, commonly known as the p21 promoter, is a vital regulatory DNA sequence that controls the expression of the p21 protein, a key mediator of cell cycle arrest (El-Deiry et al., 1993, Cell). It serves as a primary transcriptional target for the p53 tumor suppressor protein, which binds to specific response elements within the promoter to trigger G1 phase arrest following DNA damage (PubMed: 8252621). Beyond p53, the promoter is regulated by various other transcription factors and epigenetic mechanisms, including histone acetylation and DNA methylation (Gartel & Radhakrishnan, 2005, Cancer Research). In many oncogenic contexts, the p21 promoter is silenced or downregulated, facilitating unchecked cellular proliferation and survival. Pharmacological targeting of this region typically involves the use of histone deacetylase (HDAC) inhibitors, such as Vorinostat, which promote an open chromatin structure to reactivate p21 expression (Richon et al., 2000, PNAS). Other approaches include MDM2 inhibitors that stabilize p53 to enhance its binding to the promoter, making it a focal point for cancer therapies aimed at restoring cell cycle control (StatPearls: Cancer, Cell Cycle Control).

Other names

CDKN1A promoterWAF1 promoterCIP1 promoterSDI1 promoterCAP20 promoter

Transcriptional activation via epigenetic modification (HDAC inhibition, DNMT inhibition) or stabilization of upstream transcription factors like p53.